Lung-function trajectories leading to chronic obstructive pulmonary disease

New England Journal of Medicine

Volumn 373, Issue 2, 2015, Pages 111-122

  Lange, Peter ^a,b,c   Celli, Bartolome ^c,f   Agustí, Alvar ^g,i   Jensen, Gorm Boje ^a,c,e   Divo, Miguel ^f   Faner, Rosa ^h,i   Guerra, Stefano ^k   Marott, Jacob Louis ^c   Martinez, Fernando D ^k   Martinez Camblor, Pablo ^l   Meek, Paula ^m   Owen, Caroline A ^f   Petersen, Hans ⁿ   Pinto Plata, Victor ^f   Schnohr, Peter ^c   Sood, Akshay ^o   Soriano, Joan B ^j   Tesfaigzi, Yohannes ⁿ   Vestbo, Jørgen ^d,p  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Department of Cardiology   (United States)

^c FREDERIKSBERG HOSPITAL   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g UNIVERSITY OF BARCELONA   (Spain)

^h Fundacio Clinic Per a la Recerca Biomedica   (Spain)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

^j HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^k UNIVERSITY OF ARIZONA   (United States)

^l UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^m UNIVERSITY OF COLORADO   (United States)

ⁿ LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^o UNIVERSITY OF NEW MEXICO   (United States)

^p UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADULTHOOD; AGE; AGED; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COHORT ANALYSIS; CONFERENCE PAPER; DETERIORATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; ILLNESS TRAJECTORY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SMOKING; SPIROMETRY; ADVERSE EFFECTS; DISEASE COURSE; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; YOUNG ADULT;

ADULT; AGED; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; YOUNG ADULT;

EID: 84936762052     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1411532     Document Type: Conference Paper

References (37)

1. Vestbo J, Hurd SS, Agust? AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-65.
2. Fletcher CM, Peto R, Tinker CM, Speizer FE. The natural history of chronic bronchitis and emphysema. Oxford, United Kingdom: Oxford University Press, 1976.
3. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645-8.
4. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 1994; 272: 1497-505.
5. Vestbo J, S?rensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-23.
6. Pauwels RA, Löfdahl C-G, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948-53.
7. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-303.
8. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-9.
9. Decramer M, Rutten-van Mölken M, Dekhuijzen PNR, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552-60.
10. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-54.
11. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-8.
12. Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis 2012; 7: 95-9.
13. Tashkin DP. Variations in FEV1 decline over time in chronic obstructive pulmonary disease and its implications. Curr Opin Pulm Med 2013; 19: 116-24.
14. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365: 1184-92.
15. Casanova C, de Torres JP, Aguirre-Ja?me A, et al. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med 2011; 184: 1015-21.
16. Mohamed Hoesein FA, Zanen P, Boezen HM, et al. Lung function decline in male heavy smokers relates to baseline airflow obstruction severity. Chest 2012; 142: 1530-8.
17. Weiss ST, Ware JH. Overview of issues in the longitudinal analysis of respiratory data. Am J Respir Crit Care Med 1996; 154: S208-S211.
18. Kerstjens HAM, Rijcken B, Schouten JP, Postma DS. Decline of FEV1 by age and smoking status: facts, figures, and fallacies. Thorax 1997; 52: 820-7.
19. Stocks J, Hislop A, Sonnappa S. Early lung development: lifelong effect on respiratory health and disease. Lancet Respir Med 2013; 1: 728-42.
20. Sanchez-Salcedo P, Divo M, Casanova C, et al. Disease progression in young patients with COPD: rethinking the Fletcher and Peto model. Eur Respir J 2014; 44: 324-31.
21. Postma D, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet 2015; 385: 899-909.
22. Burrows B, Knudson RJ, Lebowitz MD. The relationship of childhood respiratory illness to adult obstructive airway disease. Am Rev Respir Dis 1977; 115: 751-60.
23. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159: 179-87.
24. L?kke A, Marott JL, Mortensen J, Nordestgaard BG, Dahl M, Lange P. New Danish reference values for spirometry. Clin Respir J 2012; 7: 153-67.
25. Petersen H, Sood A, Meek PM, et al. Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use. Chest 2014; 145: 695-703.
26. Sears MR, Greene JM, Willan AR, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med 2003; 349: 1414-22.
27. Stern DA, Morgan WJ, Wright AL, Guerra S, Martinez FD. Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study. Lancet 2007; 370: 758-64.
28. Bisgaard H, Jensen SM, B?nnelykke K. Interaction between asthma and lung function growth in early life. Am J Respir Crit Care Med 2012; 185: 1183-9.
29. Tai A, Tran H, Roberts M, Clarke N, Wilson J, Robertson CF. The association between childhood asthma and adult chronic obstructive pulmonary disease. Thorax 2014; 69: 805-10.
30. Svanes C, Sunyer J, Plana E, et al. Early life origins of chronic obstructive pulmonary disease. Thorax 2010; 65: 14-20.
31. Hnizdo E, Sircar K, Glindmeyer HW, Petsonk EL. Longitudinal limits of normal decline in lung function in an individual. J Occup Environ Med 2006; 48: 625-34.
32. Baughman P, Marott JL, Lange P, et al. Combined effect of lung function level and decline increases morbidity and mortality risks. Eur J Epidemiol 2012; 27: 933-43.
33. Bland JM, Altman DG. Some examples of regression towards the mean. BMJ 1994; 309: 780.
34. Kohansal R, Martinez-Camblor P, Agust? A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham Offspring Cohort. Am J Respir Crit Care Med 2009; 180: 3-10.
35. Burrows B, Lebowitz MD, Camilli AE, Knudson RJ. Longitudinal changes in forced expiratory volume in one second in adults: methodologic considerations and findings in healthy nonsmokers. Am Rev Respir Dis 1986; 133: 974-80.
36. Sherrill DL, Lebowitz MD, Knudson RJ, Burrows B. Continuous longitudinal regression equations for pulmonary function measures. Eur Respir J 1992; 5: 452-62.
37. Kohansal R, Soriano JB, Agusti A. Investigating the natural history of lung function: facts, pitfalls, and opportunities. Chest 2009; 135: 1330-41.